Aquestive Therapeutics (NASDAQ: AQST) posts new investor presentation

Rhea-AI Filing Summary

Aquestive Therapeutics, Inc. furnished a current report to share its latest investor presentation used at the H.C. Wainwright 27th Annual Global Investor Conference held on September 8, 2025. The presentation is attached as Exhibit 99.1 and may also be viewed on the company’s website. The information in this investor deck is being provided under a Regulation FD disclosure item and is expressly stated as “furnished” rather than “filed”, meaning it is not subject to liability under Section 18 of the Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001398733false00013987332025-09-082025-09-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 8, 2025

Aquestive Therapeutics, Inc.

(Exact name of Registrant as specified in its charter)

Delaware			001-38599			82-3827296
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

30 Technology Drive

Warren, NJ 07059

(908) 941-1900

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

Not Applicable

(Former name or former address, if changed since last report)

________________________________________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.001 per share			AQST			Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

Aquestive Therapeutics, Inc. (the "Company") is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation, to be given at meetings with institutional investors, analysts and others. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means. A copy of the Company's investor presentation given to investors, analysts and others at the H.C. Wainwright 27th Annual Global Investor Conference on September 8, 2025 is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The H.C. Wainwright presentation is available on the Company’s website located at www.aquestive.com, although the Company reserves the right to discontinue that availability at any time.

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of, or otherwise subject to the liabilities of, Section 18 of the Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit Number						Description
99.1						Aquestive Therapeutics, Inc. H.C. Wainwright 27th Annual Global Investor Conference Presentation dated September 8, 2025

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 8, 2025			Aquestive Therapeutics, Inc.
			By:			/s/ A. Ernest Toth, Jr
						Name: A. Ernest Toth, Jr.
						Title: Chief Financial Officer

FAQ

What did Aquestive Therapeutics (AQST) disclose in this 8-K filing?

Aquestive Therapeutics furnished an investor presentation used at the H.C. Wainwright 27th Annual Global Investor Conference on September 8, 2025, attached as Exhibit 99.1.

What is included in Exhibit 99.1 for Aquestive Therapeutics (AQST)?

Exhibit 99.1 contains the Aquestive Therapeutics, Inc. H.C. Wainwright 27th Annual Global Investor Conference Presentation dated September 8, 2025.

Is the Aquestive Therapeutics (AQST) investor presentation considered filed with the SEC?

No. The company states the information in Item 7.01, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

Can the Aquestive Therapeutics (AQST) investor presentation be accessed online?

Yes. The company notes the H.C. Wainwright presentation is available on its website at www.aquestive.com, though it may discontinue that availability at any time.

Will the Aquestive Therapeutics (AQST) investor presentation be incorporated into other SEC filings?

The company states the information in Item 7.01 and Exhibit 99.1 will only be incorporated into other Securities Act or Exchange Act filings if expressly set forth by specific reference.

Who signed this Aquestive Therapeutics (AQST) 8-K report?

The report was signed on behalf of Aquestive Therapeutics, Inc. by A. Ernest Toth, Jr, who is identified as the company’s Chief Financial Officer.